Shares in CSL Limited (ASX: CSL) could be moving in early trade after the company’s annual research and development (R&D) update.
What did CSL announce today?
CSL’s global R&D footprint now boasts over 1,700 scientists across the UK, Europe, China, Australia and the United States.
The group is collaborating with universities and institutions across the globe as it looks for innovative healthcare solutions.
Total R&D investment sits at 10–11% of global revenue and totalled $832 million in 2018–2019. This is predominantly in New Product Development with smaller allocations to Market Development and Life Cycle Management.
CSL shares could be worth watching this morning following key updates including regulatory approvals.
The healthcare giant continues to rollout its Hizentra product across Russia, Indonesia, Japan, Brazil and Mexico.
There are a number of products across the R&D pipeline, including Afluria QIV and Fluad QIV here in the registration phase here in Australia.
Senior Vice President Dr. Andrew Nash also touched on CSL’s new product opportunities. Plasma and Recombinant are 2 key areas for the group while Gene Therapy is also providing opportunities.
CSL shares have rocketed 49.91% higher this year to $277.90 as the group smashed its own ASX record high several times.
New facilities in Australia (Melbourne), Switzerland (Bern) and the United States (Pasadena) are also expanding the group’s capabilities.
CSL’s R&D pipeline includes funding and collaboration initiatives across the globe as well as venture capital investments. Biotech partnerships with Momenta and strategic partnerships such as its Walter and Eliza Hall Institute alliance are also core.
The group is seeing strong demand across its portfolio including its Immunoglobulin, Coagulation, Specialty and Albumin products.
The group’s shares will be worth watching after saying it remains on track to become a market leader in CIDP, a rare neurological disorder.
CSL shares have rocketed higher so far this year and the group’s R&D expenditure is key to its success.
The post CSL shares on watch after annual R&D update appeared first on Motley Fool Australia.
If you're looking for the next CSL for your portfolio, check out these 5 bargain stocks before Christmas!
When Edward Vesely -- our resident dividend expert -- has a stock tip, it can pay to listen. With huge winners like Dicker Data (up 147%) and Collins Food (up 105%) under his belt, Edward is building an enviable following amongst investors that are planning for retirement.
In a brand new report, Edward has just revealed what he believes are the 3 best dividend stocks for income-hungry investors to buy now. All 3 stocks are paying growing fully franked dividends giving you the opportunity to combine capital appreciation with attractive dividend yields.
Best of all, Edward’s “Top 3 Dividend Shares To Buy For 2020” report is totally free to all Motley Fool readers.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019